This module examines the therapeutic options currently available to help prevent non-alcoholic fatty liver disease (NAFLD) and its progression in people with diabetes.
Joint EASL-EASD-EASO guidelines on the clinical management of NAFLD, Diabetologia. 2016;59(6):1148-1149.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861747/pdf/125_2016_Article_3941.pdf
Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, Hollingsworth KG, Mathers JC, Sattar N, Lean M. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. Cell Metab. 2018 Oct 2;28(4):547-556.e3.
https://pubmed.ncbi.nlm.nih.gov/30078554/
By the end of this module, you will be able to:
✓ Outline the potential benefits and limitations of lifestyle interventions on the prevention and treatment of NAFLD
✓ Explain why interventions that result in significant and sustainable weight loss are so important to preventing NAFLD and its progression
✓ Compare the potential uses of type 2 diabetes medications to treat NAFLD
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.